Tri-Institutional Tuberculosis Research Advancement Center (TRAC)

三机构结核病研究促进中心 (TRAC)

• 批准号: 10430737
• 负责人: Daniel W Fitzgerald
• 金额: $ 103.44万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10430737
• 关键词: Address; Animal Model; Area; Award; Basic Science; Biochemistry; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communication Programs; Development; Discipline; Educational workshop; Environment; Faculty; Fostering; Funding; Genetic; Goals; Haiti; Human Genetics; Immunology; Institution; Interdisciplinary Study; International; Leadership; Libraries; Maps; Medicine; Memorial Sloan-Kettering Cancer Center; Mentorship; Microbiology; Minority Women; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; New York City; Postdoctoral Fellow; Prevention; Program Evaluation; Research; Research Personnel; Research Priority; Research Project Grants; Research Training; Resources; Sampling; Science; Scientist; Site; Strategic Planning; Tanzania; Technical Expertise; Technology; Translational Research; Travel; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Universities; Woman; biobank; career; clinical research site; drug discovery; experience; implementation science; improved; innovation; member; mortality; multidisciplinary; mycobacterial; organizational structure; programs; recruit; symposium; tuberculosis diagnostics

Overall Abstract: We propose a Tri-Institutional Tuberculosis (TB) Research Advancement Center (TRAC) at Weill Cornell Medicine, Memorial Sloan-Kettering Cancer Center and Rockefeller University. The three institutions are adjacent to each other on a Tri-Institutional (Tri-I) campus in New York City. The purpose of the proposed Tri-I TRAC is to pool the expertise and resources of an outstanding team of 20 senior TB investigators at the three institutions to expand the number of investigators in the field of TB research and to promote innovative multidisciplinary TB research. The senior investigators have diverse expertise spanning biochemistry, basic microbiology, mycobacterial genetics, human genetics and immunology, drug discovery, international clinical trials, and implementation science. A major focus will be supporting New Investigators (NIs), who we define as senior post-doctoral fellows or junior faculty members who seek an academic career and have not yet received an R01. We also will recruit New to TB (N2TB) Investigators, who are R01 experienced investigators in other scientific disciplines who bring their expertise to study TB. The TRAC will have four Cores. The Administrative Core will provide leadership, financial oversight, communication, and program evaluation. A Developmental Core will fund 6 Developmental Project Awards annually of $50,000 each to support NIs and N2TB investigators. Institutional support from Weill Cornell Medicine will fund two of these awards each year which will be designated for under-represented minorities and women scientists. The Clinical Core will build upon long-standing collaborations primarily in Haiti and also in Tanzania. The Basic and Clinical Science Cores will provide NI and N2TB recipients of Developmental Project Awards mentorship, technical expertise, and scientific resources unique to TB research including access to TB animal models, genetically modified mycobacterial libraries, and biobanked clinical samples. The Basic and Clinical Science Cores will also facilitate sharing of technology and resources between senior TB investigators in order to initiate new lines of collaborative translational TB research. Other activities including an annual symposium, a technology workshop, and travel to international TB clinical sites will bolster the pipeline of new TB investigators and generate an environment conducive to multidisciplinary collaboration. There will be no overlap with other NIH research grants, centers, or institutional cores. The TRAC will leverage these existing resources and synergistically expand the number of TB investigators and foster new innovative lines of collaboration. Our goal over 5 years is to have 25 NIs successfully compete for a TB related NIH R01 and transition to independence and to attract at least 5 N2TB investigators to TB science. Half will be women and at least 20% underrepresented minorities. We will also initiate new lines of collaborative translational research to address the five NIAID priorities in TB science with the ultimate goal of improving TB diagnostics, prevention, and treatment and ending morbidity and mortality from TB world-wide.

总体摘要：我们提出了三机构结核病（TB）研究进步中心 （TRAC）在Weill Cornell Medicine，Sloan-Kettering Cancer Center和Rockefeller University。这 在纽约市的三机构（TRI-I）校园里，三个机构彼此相邻。目的 拟议的Tri-i Trac是汇集20名高级结核病的杰出团队的专业知识和资源 这三个机构的调查人员扩大了结核病研究领域的调查人员人数和 促进创新的多学科结核病研究。高级调查人员具有多样的专业知识 跨越生物化学，基本微生物学，分枝杆菌遗传学，人类遗传学和免疫学，药物 发现，国际临床试验和实施科学。重点将支持新的 调查人员（NIS），我们将其定义为高级博士后研究员或初级教师 学术生涯，尚未获得R01。我们还将招募新的结核病（N2TB）调查员， 他们是R01的其他科学学科的经验丰富的研究人员，他们将其专业知识带入研究结核病。这 TRAC将有四个核心。行政核心将提供领导，财务监督， 沟通和计划评估。发展核心将资助6个发展项目奖 每年每年50,000美元，以支持NIS和N2TB调查人员。威尔·康奈尔（Weill Cornell）的机构支持 医学每年将为其中两个奖项提供资金，这些奖项将被指定为代表性不足的少数民族 和女科学家。临床核心将基于长期合作，主要在海地和 也在坦桑尼亚。基本和临床科学核心将为NI和N2TB提供发育的接受者 TB研究独有的项目奖励指导，技术专长和科学资源包括 访问结核病模型，基因修饰的分枝杆菌文库以及生物库临床样本。这 基础和临床科学核心还将促进高级结核病之间的技术和资源共享 调查人员为了启动合作转化结核病研究的新系列。其他活动，包括 年度研讨会，技术研讨会以及前往国际结核病临床站点的旅行将加强 新的结核病研究人员的管道，并产生一个有利于多学科合作的环境。 其他NIH研究补助金，中心或机构核心不会重叠。 trac将利用 这些现有资源，并协同扩大结核病研究人员的数量并培养新的创新性 协作线。我们5年以上的目标是让25个NIS成功竞争与结核病相关的NIH R01 并过渡到独立性，并至少吸引5名N2TB调查人员到结核病科学。一半会 妇女和至少20％的人数不足的少数民族。我们还将启动新的协作线 转化研究以解决结核病科学的五个NIAID优先事项，其最终目的是改善结核病 诊断，预防以及治疗以及结核病世界范围内的发病率和死亡率。